Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours Β· Estimated delivery Aug 12 - Aug 17
Laboratory studies demonstrate that combinations of improved senolytic peptides (such as ES2, which shows 3-7 times greater efficacy than FOXO4-DRI) with chemotherapeutic agents like Dabrafenib result in greater elimination of both cancer and senescent cells
Ask about their experience, monitoring process and whether this therapy aligns with your goals
The safety profile is generally favorable, with most side effects being GI-related (nausea, constipation, diarrhea) that improve with time and gradual dose escalation
Start: Begin around 300 mcg per day to gauge tolerability, then adjust as needed
US$ 22.83
US$ 28.73
US$ 25.35
US$ 23.23
US$ 26.19
US$ 23.01
